Agenda

See the 2019 Agenda Below!

The Cell & Gene Meeting on the Med features expert-led panels, in-depth keynote speeches, interactive fireside chats, and 50+ presentations by leading publicly traded and privately held companies from around the globe.

The agenda below is from the 2019 conference. More information on the 2020 agenda will be released at a future date.

Quick Links

WEBCAST ATTENDEES SPONSORS

8:00am – 9:00am | REGISTRATION

9:00am | GENERAL SESSION AND PARTNERING OPENS

9:00am – 9:15am

WELCOME AND STATE OF THE INDUSTRY REMARKS {Gaudi 3}

Speaker:

Janet Lynch Lambert, CEO, Alliance for Regenerative Medicine (ARM)

9:15am – 9:45am

KEYNOTE ADDRESS {Gaudi 3}

Speaker:

Guido Rasi, M.D., Director General, European Medicines Agency (EMA)

9:45am – 10:45am

PLENARY SESSION: COMMERCIAL STRATEGIES FROM PATHFINDERS IN THE INDUSTRY {Gaudi 3}

Chair:

Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult

Speakers:

Dan Faga, Chief Business Officer, Spark Therapeutics
Alison Finger, Chief Commercial Officer, bluebird bio
Claire Foreman, Head of Acute Programs, National Health Service
Owen Marks, Rare Disease Lead, Pfizer UK
Pascal Touchon, SVP and Global Head, Cell and Gene, Novartis Oncology

10:45am – 11:15am | MORNING BREAK
Sponsored by Bio-Techne

11:15am – 12:30pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS {Gaudi 3}

11:15am – 11:30am

uniQure

11:30am – 11:45am

Sangamo Therapeutics

11:45am – 12:00pm

Orchard Therapeutics

12:00pm – 12:15pm

REGENXBIO

12:15pm – 12:30pm

Audentes Therapeutics

COMPANY PRESENTATIONS {Gaudi 2}

11:15am – 11:30am

Aspect Biosystems

11:30am – 11:45am

NAVAN Technologies

11:45am – 12:00pm

LogicBio

12:00pm – 12:15pm

VERIGRAFT

12:15pm – 12:30pm

Bone Therapeutics

12:30pm – 1:45pm | LUNCH
Sponsored by Terumo BCT

1:45pm – 3:30pm | CONCURRENT TRACKS

PANEL: THE PRICING AND REIMBURSEMENT LANDSCAPE: OPPORTUNITIES AND CHALLENGES {Gaudi 3}
1:45pm – 2:45pm

Chair:

Tom Baker, VP, Life Science Strategy and Pricing and Market Access, IQVIA

Speakers:

Luca Alberici, Ph.D., Chief Business Officer, MolMed

Etienne Jousseaume, Head of Market Access, Cell and Gene Europe, Novartis

Jason Meyenburg, Chief Commercial Officer, Orchard Therapeutics

COMPANY PRESENTATIONS {Gaudi 2}

1:45pm – 2:00pm

FUJIFILM Cellular Dynamics

2:00pm – 2:15pm

Cynata Therapeutics

2:15pm – 2:30pm

BlueRock Therapeutics

2:30pm – 2:45pm

3Scan

COMPANY PRESENTATIONS {Gaudi 3}

2:45pm – 3:00pm

MaxCyte

3:00pm – 3:15pm

Spark Therapeutics

3:15pm – 3:30pm

ReNeuron

COMPANY PRESENTATIONS {Gaudi 2}

2:45pm – 3:00pm

CEVEC Pharmaceuticals

3:00pm – 3:15pm

TikoMed

3:15pm – 3:30pm

ORIG3N

3:30pm – 4:00pm | AFTERNOON BREAK
Sponsored by Bio-Techne

4:00pm – 5:30pm | CONCURRENT TRACKS

SPOTLIGHT SESSION: CELL THERAPY FOR SOLID TUMORS {Gaudi 3}
4:00pm – 4:30pm

Chair:

Alexander Pasteur, Ph.D., Partner, F-Prime Capital

Speakers:

Usman Azam, M.D., President and CEO, Tmunity Therapeutics

Kimberly Freeman, VP, Commercial, Adaptimmune

COMPANY PRESENTATIONS {Gaudi 2}

4:00pm – 4:15pm

T-knife

4:15pm – 4:30pm

Zelluna Immunotherapy

PANEL: MANUFACTURING AND THE CDMO PERSPECTIVE {Gaudi 3}
4:30pm – 5:30pm

Chair:

Thomas Fellner, Ph.D., Global Head of Business Development and Account Management, Cell and Gene Technologies, Lonza

Speakers:

Catherine Cancian, VP, Pharmaceutical Operations, GenSight Biologics

Frédéric Revah, Ph.D., President, Yposkesi; CEO, Genethon

Joseph Tarnowski, Ph.D., SVP, Cell and Gene Therapy Platforms, Medicinal Science and Technology, R&D, GSK

Kim Warren, Head of Operations, AVROBIO

COMPANY PRESENTATIONS {Gaudi 2}

4:30pm – 4:45pm

Sigilon Therapeutics

4:45pm – 5:00pm

Tmunity Therapeutics

5:00pm – 5:15pm

Chimeric Therapeutics

5:15pm – 5:30pm

Avectas

5:30pm | PARTNERING CLOSES

6:30pm – 9:30pm | NETWORKING BASH
Lokal Restaurant Terrace and Garden

8:00am – 9:00am | REGISTRATION

9:00am | GENERAL SESSION AND PARTNERING OPENS

9:00am – 9:15am

WELCOME REMARKS {Gaudi 3}

Speaker:

Matthew Patterson, Chairman and CEO, Audentes Therapeutics; Chairman, Alliance for Regenerative Medicine (ARM)

9:15am – 10:45am | CONCURRENT TRACKS

PANEL: RECENT DEVELOPMENTS AND PREDICTIONS FOR THE FUTURE OF ADVANCED THERAPIES {Gaudi 3}
9:15am – 10:15am

Chair:

Morrie Ruffin, Co-Founder and Senior Advisor, Alliance for Regenerative Medicine (ARM)

Speakers:

Amy DuRoss, Co-Founder and CEO, Vineti

Sven Kili, M.D., Principal, Sven Kili Consulting

John Tchelingerian, Ph.D., President and CEO, Promethera Biosciences

Christopher Vann, Chief Operating Officer, Autolus Therapeutics

Rogerio Vivaldi, M.D., President and CEO, Sigilon Therapeutics

COMPANY PRESENTATIONS {Gaudi 2}

9:15am – 9:30am

FloDesign Sonics

9:30am – 9:45am

Rexgenero

9:45am – 10:00am

PanCELLa

10:00am – 10:15am

Organovo

SPOTLIGHT SESSION: GENE EDITING: PARTNERING FOR SUCCESS {Gaudi 3}
10:15am – 10:45am

Chair:

Jessica Carmen, Ph.D., U.S. Business Development Advisor, Oxford BioMedica

Speakers:

Timothy Herpin, Ph.D., Chief Business Officer, Caribou Biosciences

Peter Nell, Ph.D., VP, Strategy and Business Development, Casebia Therapeutics

COMPANY PRESENTATIONS {Gaudi 2}

10:15am – 10:30am

DiscGenics

10:30am – 10:45am

MolMed

10:45am – 11:15am | MORNING BREAK
Sponsored by Bio-Techne

11:15am – 12:30pm | CONCURRENT TRACKS

COMPANY PRESENTATIONS {Gaudi 3}

11:15am – 11:30am

Oxford BioMedica

11:30am – 11:45am

bluebird bio

11:45am – 12:00pm

Adaptimmune

12:00pm – 12:15pm

Iovance Biotherapeutics

12:15pm – 12:30pm

Kiadis Pharma

COMPANY PRESENTATIONS {Gaudi 2}

11:15am – 11:30am

Promethera Biosciences

11:30am – 11:45am

Vivet Therapeutics

11:45am – 12:00pm

Genethon

12:00pm – 12:15pm

Axovant

12:15pm – 12:30pm

AGTC

12:30pm – 1:45pm | LUNCH
Sponsored by Terumo BCT

1:45pm – 3:00pm | CONCURRENT TRACKS

PANEL: EUROPEAN CLINICAL TRIALS IN A GLOBAL CONTEXT {Gaudi 3}
1:45pm – 2:30pm

Chair:

Timothy Schroeder, CEO, CTI Clinical Trial & Consulting Services

Speakers:

Ian Hudson, M.D., Chief Executive, Medicines and Healthcare Products Regulatory Agency (MHRA)

Nathalie Morgensztejn, Head of Virology and Gene Therapy Department, French National Agency for Medicines and Health Products Safety (ANSM)

Ilona Reischl, Ph.D., Institute Surveillance, Federal Office for Safety in Health Care, Austrian Agency for Health and Food Safety

Martina Schüssler-Lenz, M.D., Chair, EMA Committee for Advanced Therapies, Paul-Ehrlich-Institut

Katsuaki Ura, Deputy Director, Office of International Regulatory Affairs, Pharmaceutical Safety and Environmental Health Bureau, Ministry of Health, Labour and Welfare (MHLW)

COMPANY PRESENTATIONS {Gaudi 2}

1:45pm – 2:00pm

B-MoGen Biotechnologies

2:00pm – 2:15pm

PDC*line Pharma

2:15pm – 2:30pm

Caribou Biosciences

FIRESIDE CHAT: REGULATING ATMPs IN A POST BREXIT WORLD {Gaudi 3}
2:30pm – 3:00pm

Chair:

Keith Thompson, CEO, Cell and Gene Therapy Catapult

Speaker:

Ian Hudson, M.D., Chief Executive, Medicines and Healthcare Products Regulatory Agency (MHRA)